{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T09:26:56Z","timestamp":1786958816846,"version":"build-2736575974"},"reference-count":98,"publisher":"European Respiratory Society (ERS)","issue":"4","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2024-00439277"],"award-info":[{"award-number":["RS-2024-00439277"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2026,1,23]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) is a distinct clinical syndrome characterised by moderate-to-severe asthma and a high prevalence of chronic rhinosinusitis with nasal polyps and aspirin\/NSAID intolerance. The primary pathogenesis of N-ERD includes the dysregulation of arachidonic acid metabolism with subsequent cysteinyl leukotriene overproduction and persistent type 2\/eosinophilic inflammation in the upper and lower airways. N-ERD has considerably heterogeneous clinical features and courses, emphasising the necessity for classifying its phenotypes and\/or endotypes to enable early diagnosis and individualised treatment approaches. However, the lack of reliable and standardised tests and biomarkers can cause diagnostic delays, leading to inadequate management and more severe disease progression in affected individuals. Current treatments for N-ERD include NSAID avoidance, aspirin desensitisation, and the use of leukotriene modifiers and corticosteroids. Recently, biologics targeting interleukin (IL)-4, IL-5, IL-13 and IgE have been suggested as treatment options, particularly for patients with high type 2 inflammatory burden. However, the treatment responses in this patient population remain variable, highlighting the need for individualised therapeutic strategies. In this review, we summarise recent insights into the pathogenic mechanisms, clinical manifestations, and phenotype classification of N-ERD, evaluate emerging biomarkers, and explore the potential of targeted therapies within the framework of precision medicine.<\/jats:p>","DOI":"10.1183\/23120541.01484-2025","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:55:19Z","timestamp":1771268119000},"page":"01484-2025","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Toward precision medicine in nonsteroidal anti-inflammatory drug-exacerbated respiratory disease"],"prefix":"10.1183","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1564-3511","authenticated-orcid":false,"given":"Soyoon","family":"Sim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo Seob","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae-Sim","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"2026081701451734000_12.4.01484-2025.1","doi-asserted-by":"crossref","first-page":"647257","DOI":"10.3389\/fgene.2021.647257","article-title":"Pharmacogenomics of hypersensitivity to non-steroidal anti-inflammatory drugs","volume":"12","author":"Trinh","year":"2021","journal-title":"Front Genet"},{"key":"2026081701451734000_12.4.01484-2025.2","doi-asserted-by":"publisher","DOI":"10.1111\/all.12881"},{"key":"2026081701451734000_12.4.01484-2025.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.020"},{"key":"2026081701451734000_12.4.01484-2025.4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1164\/ajrccm\/146.1.76","article-title":"Long-term prognosis of near-fatal asthma. A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma","volume":"146","author":"Marquette","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"2026081701451734000_12.4.01484-2025.5","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3389\/fphar.2020.01147","article-title":"NSAID-exacerbated respiratory disease (NERD): from pathogenesis to improved care","volume":"11","author":"Woo","year":"2020","journal-title":"Front Pharmacol"},{"key":"2026081701451734000_12.4.01484-2025.6","doi-asserted-by":"publisher","DOI":"10.1111\/all.13599"},{"key":"2026081701451734000_12.4.01484-2025.7","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/cea.14362","article-title":"Long-term clinical outcomes of aspirin-exacerbated respiratory disease: real-world data from an adult asthma cohort","volume":"53","author":"Lee","year":"2023","journal-title":"Clin Exp Allergy"},{"key":"2026081701451734000_12.4.01484-2025.8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaci.2013.07.004","article-title":"Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis","volume":"133","author":"Bochenek","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2026081701451734000_12.4.01484-2025.9","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/all.14141","article-title":"Subphenotypes of nonsteroidal antiinflammatory disease-exacerbated respiratory disease identified by latent class analysis","volume":"75","author":"Celejewska-W\u00f3jcik","year":"2020","journal-title":"Allergy"},{"key":"2026081701451734000_12.4.01484-2025.10","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/all.13075","article-title":"Identification of phenotypic clusters of nonsteroidal anti-inflammatory drugs exacerbated respiratory disease","volume":"72","author":"Lee","year":"2017","journal-title":"Allergy"},{"key":"2026081701451734000_12.4.01484-2025.11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4168\/aair.2022.14.2.153","article-title":"Emerging biomarkers beyond leukotrienes for the management of nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease","volume":"14","author":"Rhyou","year":"2022","journal-title":"Allergy Asthma Immunol Res"},{"key":"2026081701451734000_12.4.01484-2025.12","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4168\/aair.2025.17.2.226","article-title":"Analysis of miRNA expression in patients with NSAID-exacerbated respiratory disease","volume":"17","author":"Gajewski","year":"2025","journal-title":"Allergy Asthma Immunol Res"},{"key":"2026081701451734000_12.4.01484-2025.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2006.02498.x"},{"key":"2026081701451734000_12.4.01484-2025.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2012.11.006"},{"key":"2026081701451734000_12.4.01484-2025.15","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4168\/aair.2024.16.5.462","article-title":"Update on inflammatory biomarkers for defining asthma phenotype","volume":"16","author":"Sim","year":"2024","journal-title":"Allergy Asthma Immunol Res"},{"key":"2026081701451734000_12.4.01484-2025.16","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.23.3.4051"},{"key":"2026081701451734000_12.4.01484-2025.17","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.107603"},{"key":"2026081701451734000_12.4.01484-2025.18","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.153.1.8542168"},{"key":"2026081701451734000_12.4.01484-2025.19","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/143.5_Pt_1.1025"},{"key":"2026081701451734000_12.4.01484-2025.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.04.031"},{"key":"2026081701451734000_12.4.01484-2025.21","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jaci.2023.03.015","article-title":"Mechanistic and clinical updates in AERD: 2021\u20132022","volume":"151","author":"Stevens","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2026081701451734000_12.4.01484-2025.22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/all.70034","article-title":"Omics in NSAID-exacerbated respiratory disease: current evidence from the upper and lower airways","volume":"81","author":"iAkushev","year":"2026","journal-title":"Allergy"},{"key":"2026081701451734000_12.4.01484-2025.23","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jaci.2025.03.006","article-title":"Clinical and mechanistic advancements in aspirin exacerbated respiratory disease","volume":"155","author":"Elahi","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"2026081701451734000_12.4.01484-2025.24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/ACI.0000000000000498","article-title":"Prostaglandin E2 in NSAID-exacerbated respiratory disease: protection against cysteinyl leukotrienes and group 2 innate lymphoid cells","volume":"19","author":"Rusznak","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2026081701451734000_12.4.01484-2025.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.01.065"},{"key":"2026081701451734000_12.4.01484-2025.26","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2745.2002.01507.x"},{"key":"2026081701451734000_12.4.01484-2025.27","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jaci.2015.10.020","article-title":"Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease","volume":"137","author":"Buchheit","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2026081701451734000_12.4.01484-2025.28","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jaci.2010.12.1108","article-title":"Targeted eicosanoid lipidomics of exhaled breath condensate provide a distinct pattern in the aspirin-intolerant asthma phenotype","volume":"127","author":"Sanak","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"2026081701451734000_12.4.01484-2025.29","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1387"},{"key":"2026081701451734000_12.4.01484-2025.30","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.jaip.2024.01.029","article-title":"Absolute eosinophil counts in aspirin-exacerbated respiratory disease are distinctly elevated and correlate inversely with respiratory function","volume":"12","author":"Supron","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026081701451734000_12.4.01484-2025.31","doi-asserted-by":"publisher","DOI":"10.1172\/JCI620"},{"key":"2026081701451734000_12.4.01484-2025.32","doi-asserted-by":"publisher","DOI":"10.1002\/lary.21969"},{"key":"2026081701451734000_12.4.01484-2025.33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.plefa.2014.02.006","article-title":"Biological effects of leukotriene E4 on eosinophils","volume":"91","author":"Steinke","year":"2014","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"2026081701451734000_12.4.01484-2025.34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/intimm\/dxy061","article-title":"Eosinophil-derived neurotoxin enhances airway remodeling in eosinophilic chronic rhinosinusitis and correlates with disease severity","volume":"31","author":"Tsuda","year":"2019","journal-title":"Int Immunol"},{"key":"2026081701451734000_12.4.01484-2025.35","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1111\/all.15780","article-title":"Peripheral biomarkers for predicting sputum eosinophilia in nonsteroidal anti-inflammatory drug-exacerbated respiratory disease","volume":"78","author":"Tr\u0105d","year":"2023","journal-title":"Allergy"},{"key":"2026081701451734000_12.4.01484-2025.36","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2020.08.007","article-title":"Heterogeneity of lower airway inflammation in patients with NSAID-exacerbated respiratory disease","volume":"147","author":"Jakiela","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2026081701451734000_12.4.01484-2025.37","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jaci.2018.02.024","article-title":"Leukotriene E4 induces airflow obstruction and mast cell activation through the cysteinyl leukotriene type 1 receptor","volume":"142","author":"Lazarinis","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2026081701451734000_12.4.01484-2025.38","doi-asserted-by":"crossref","first-page":"320","DOI":"10.4168\/aair.2019.11.3.320","article-title":"Which factors associated with activated eosinophils contribute to the pathogenesis of aspirin-exacerbated respiratory disease?","volume":"11","author":"Choi","year":"2019","journal-title":"Allergy Asthma Immunol Res"},{"key":"2026081701451734000_12.4.01484-2025.39","doi-asserted-by":"publisher","DOI":"10.1038\/nri3831"},{"key":"2026081701451734000_12.4.01484-2025.40","doi-asserted-by":"crossref","first-page":"851940","DOI":"10.3389\/fphar.2022.851940","article-title":"Interleukins 4 and 13 in asthma: key pathophysiologic cytokines and druggable molecular targets","volume":"13","author":"Pelaia","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026081701451734000_12.4.01484-2025.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.12.958"},{"key":"2026081701451734000_12.4.01484-2025.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.10.056"},{"key":"2026081701451734000_12.4.01484-2025.43","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2015-0295OC"},{"key":"2026081701451734000_12.4.01484-2025.44","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jaci.2020.04.064","article-title":"Inflammatory macrophage memory in nonsteroidal anti-inflammatory drug-exacerbated respiratory disease","volume":"147","author":"Haimerl","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2026081701451734000_12.4.01484-2025.45","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jaci.2020.09.040","article-title":"Macrophages and acylcarnitines: new players in aspirin-exacerbated respiratory disease?","volume":"147","author":"Laidlaw","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2026081701451734000_12.4.01484-2025.46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01409.x"},{"key":"2026081701451734000_12.4.01484-2025.47","first-page":"77","article-title":"Evaluation of risk factors causing diagnostic delay in non-steroidal anti-inflammatory drug-exacerbated respiratory disease","volume":"26","author":"Cihanbeylerden","year":"2025","journal-title":"Thorac Res Pract"},{"key":"2026081701451734000_12.4.01484-2025.48","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70324-6"},{"key":"2026081701451734000_12.4.01484-2025.49","doi-asserted-by":"crossref","first-page":"e12229","DOI":"10.1002\/clt2.12229","article-title":"Association of eosinophil-derived neurotoxin levels with asthma control status in patients with aspirin-exacerbated respiratory disease","volume":"13","author":"Ban","year":"2023","journal-title":"Clin Transl Allergy"},{"key":"2026081701451734000_12.4.01484-2025.50","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/all.16281","article-title":"Aspirin hypersensitivity diagnostic index (AHDI): in vitro test for diagnosing of N-ERD based on urinary 15-oxo-ETE and LTE4 excretion","volume":"80","author":"Mastalerz","year":"2025","journal-title":"Allergy"},{"key":"2026081701451734000_12.4.01484-2025.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.07.031"},{"key":"2026081701451734000_12.4.01484-2025.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.12.977"},{"key":"2026081701451734000_12.4.01484-2025.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.02.029"},{"key":"2026081701451734000_12.4.01484-2025.54","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.154.6.8970343"},{"key":"2026081701451734000_12.4.01484-2025.55","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.anai.2021.03.010","article-title":"Dupilumab increases aspirin tolerance in aspirin-exacerbated respiratory disease","volume":"126","author":"Mustafa","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026081701451734000_12.4.01484-2025.56","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaci.2023.03.030","article-title":"Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease","volume":"152","author":"Laidlaw","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2026081701451734000_12.4.01484-2025.57","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaip.2021.09.050","article-title":"Omalizumab-induced aspirin tolerance in nonsteroidal anti-inflammatory drug-exacerbated respiratory disease patients is independent of atopic sensitization","volume":"10","author":"Quint","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026081701451734000_12.4.01484-2025.58","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2026081701451734000_12.4.01484-2025.59","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/1945892420961969","article-title":"Dupilumab as add-on therapy for chronic rhinosinusitis with nasal polyposis in aspirin exacerbated respiratory disease","volume":"35","author":"Mustafa","year":"2021","journal-title":"Am J Rhinol Allergy"},{"key":"2026081701451734000_12.4.01484-2025.60","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(95)70290-3"},{"key":"2026081701451734000_12.4.01484-2025.61","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1016\/j.jaip.2019.04.042","article-title":"Cross-reactivity and tolerability of celecoxib in adult patients with NSAID hypersensitivity","volume":"7","author":"Li","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026081701451734000_12.4.01484-2025.62","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4168\/aair.2014.6.2.156","article-title":"Cross-reactivity to acetaminophen and celecoxib according to the type of nonsteroidal anti-inflammatory drug hypersensitivity","volume":"6","author":"Kim","year":"2014","journal-title":"Allergy Asthma Immunol Res"},{"key":"2026081701451734000_12.4.01484-2025.63","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/all.15714","article-title":"Global initiative for asthma: 30\u2005years of promoting evidence-based asthma care","volume":"78","author":"Yorgancio\u011flu","year":"2023","journal-title":"Allergy"},{"key":"2026081701451734000_12.4.01484-2025.64","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin20.600"},{"key":"2026081701451734000_12.4.01484-2025.65","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.4.9707089"},{"key":"2026081701451734000_12.4.01484-2025.66","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2108138"},{"key":"2026081701451734000_12.4.01484-2025.67","doi-asserted-by":"crossref","first-page":"298","DOI":"10.4168\/aair.2016.8.4.298","article-title":"Update on the management of aspirin-exacerbated respiratory disease","volume":"8","author":"Buchheit","year":"2016","journal-title":"Allergy Asthma Immunol Res"},{"key":"2026081701451734000_12.4.01484-2025.68","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1159\/000508708","article-title":"AERD associated nasal polyposis: efficacy of postoperative antileukotriene therapy in comparison with aspirin desensitization. A retrospective study","volume":"181","author":"San Nicol\u00f3","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"2026081701451734000_12.4.01484-2025.69","doi-asserted-by":"crossref","first-page":"e12296","DOI":"10.1002\/clt2.12296","article-title":"Risk factors of NSAID-exacerbated respiratory disease: a population-based study","volume":"13","author":"Helev\u00e4","year":"2023","journal-title":"Clin Transl Allergy"},{"key":"2026081701451734000_12.4.01484-2025.70","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/all.15067","article-title":"Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials","volume":"77","author":"Mullol","year":"2022","journal-title":"Allergy"},{"key":"2026081701451734000_12.4.01484-2025.71","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.jaip.2019.03.044","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026081701451734000_12.4.01484-2025.72","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32218-4"},{"key":"2026081701451734000_12.4.01484-2025.73","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaci.2022.04.007","article-title":"Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease","volume":"150","author":"Buchheit","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2026081701451734000_12.4.01484-2025.74","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01335-2022"},{"key":"2026081701451734000_12.4.01484-2025.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.09.007"},{"key":"2026081701451734000_12.4.01484-2025.76","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.112374"},{"key":"2026081701451734000_12.4.01484-2025.77","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201906-1215OC"},{"key":"2026081701451734000_12.4.01484-2025.78","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4168\/aair.2018.10.2.121","article-title":"Therapeutic effect of omalizumab in severe asthma: a real-world study in Korea","volume":"10","author":"Lee","year":"2018","journal-title":"Allergy Asthma Immunol Res"},{"key":"2026081701451734000_12.4.01484-2025.79","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2500\/aap.2019.40.4241","article-title":"Effect of omalizumab on outcomes in patients with aspirin-exacerbated respiratory disease","volume":"40","author":"Jean","year":"2019","journal-title":"Allergy Asthma Proc"},{"key":"2026081701451734000_12.4.01484-2025.80","first-page":"226","article-title":"Omalizumab in patients with NSAIDs-exacerbated respiratory disease","volume":"58","author":"Forster-Ruhrmann","year":"2020","journal-title":"Rhinology"},{"key":"2026081701451734000_12.4.01484-2025.81","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/19458924211030486","article-title":"Defining the efficacy of omalizumab in nasal polyposis: a POLYP 1 and POLYP 2 subgroup analysis","volume":"36","author":"Damask","year":"2022","journal-title":"Am J Rhinol Allergy"},{"key":"2026081701451734000_12.4.01484-2025.82","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.anai.2018.05.007","article-title":"Omalizumab can inhibit respiratory reaction during aspirin desensitization","volume":"121","author":"Lang","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026081701451734000_12.4.01484-2025.83","doi-asserted-by":"crossref","first-page":"40","DOI":"10.18176\/jiaci.0285","article-title":"Prospective open-label study of 48-week subcutaneous administration of mepolizumab in Japanese patients with severe eosinophilic asthma","volume":"29","author":"Kurosawa","year":"2019","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2026081701451734000_12.4.01484-2025.84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.05.043"},{"key":"2026081701451734000_12.4.01484-2025.85","doi-asserted-by":"crossref","first-page":"384","DOI":"10.4168\/aair.2025.17.3.384","article-title":"Real-world effectiveness and safety of mepolizumab in severe eosinophilic asthma: insights from the Korean severe asthma registry (KoSAR)","volume":"17","author":"Park","year":"2025","journal-title":"Allergy Asthma Immunol Res"},{"key":"2026081701451734000_12.4.01484-2025.86","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaip.2018.08.021","article-title":"Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps","volume":"7","author":"Weinstein","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026081701451734000_12.4.01484-2025.87","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/all.14902","article-title":"Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis","volume":"77","author":"Canonica","year":"2022","journal-title":"Allergy"},{"key":"2026081701451734000_12.4.01484-2025.88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2414482"},{"key":"2026081701451734000_12.4.01484-2025.89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.09.009"},{"key":"2026081701451734000_12.4.01484-2025.90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.06.019"},{"key":"2026081701451734000_12.4.01484-2025.91","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60692-8"},{"key":"2026081701451734000_12.4.01484-2025.92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.02.041"},{"key":"2026081701451734000_12.4.01484-2025.93","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-012-2048-x"},{"key":"2026081701451734000_12.4.01484-2025.94","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/1945892418770260","article-title":"Long-term clinical outcomes of aspirin desensitization with continuous daily aspirin therapy in aspirin-exacerbated respiratory disease","volume":"32","author":"Walters","year":"2018","journal-title":"Am J Rhinol Allergy"},{"key":"2026081701451734000_12.4.01484-2025.95","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaci.2020.10.043","article-title":"The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: a Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology","volume":"147","author":"Stevens","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2026081701451734000_12.4.01484-2025.96","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1586\/1744666X.2014.901889","article-title":"Topical nasal lysine aspirin in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis with nasal polyposis","volume":"10","author":"Parikh","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"2026081701451734000_12.4.01484-2025.97","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1007\/s00405-021-07063-2","article-title":"A retrospective study on long-term efficacy of intranasal lysine-aspirin in controlling NSAID-exacerbated respiratory disease","volume":"279","author":"Pendolino","year":"2022","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"2026081701451734000_12.4.01484-2025.98","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1016\/j.jaip.2024.09.012","article-title":"Current goals of NSAID-ERD management: patient-centered approaches involving NSAID desensitization with and without biologics","volume":"12","author":"Bobolea","year":"2024","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.01484-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:45:33Z","timestamp":1786956333000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.01484-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":98,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,17]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1183\/23120541.01484-2025"],"URL":"https:\/\/doi.org\/10.1183\/23120541.01484-2025","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]}}}